Back to results
US 2006/0069271 A1Published application
Alpha crystalline form of strontium ranelate
AssigneeLes Laboratoires Servier
InventorsStephane Horvath, Isabelle Demuynck, Gerard Damien
Life of this patent
Estimating the term…
Abstract
Alpha crystalline form of strontium ranelate of formula (I): characterised by its powder X-ray diffraction diagram and by a water content of from 22 to 24%. Medicinal products containing the same which are useful in the treatment of osteoporosis and arthrosis.
Claims5
The alpha crystalline form of the compound of formula (I):
- wherein the compound has a water content of from 22 to 24% and exhibits essentially the following powder x-ray diffraction diagram measured using a PANalytical X'Pert pro diffractometer together with an X'Celerator detector and expressed in terms of ray position (Bragg's angle 2 theta, expressed in degrees), ray height (expressed in counts), ray area (expressed in counts×degrees), ray width at half-height (“FWHM”, expressed in degrees) and interplanar distance d (expressed in Å):
- Surface
- Angle 2 theta
- Height
- (counts ×
- FWHM
- Interplanar
- Ray no.
- (degrees)
- (counts)
- degrees)
- (degrees)
- distance (Å)
- 1
- 7.6
- 4527
- 448
- 0.1004
- 11.649
- 2
- 8.0
- 1438
- 142
- 0.1004
- 11.069
- 3
- 8.3
- 3522
- 349
- 0.1004
- 10.642
- 4
- 8.6
- 11347
- 1123
- 0.1004
- 10.272
- 5
- 8.9
- 7332
- 726
- 0.1004
- 9.889
- 6
- 11.0
- 1047
- 104
- 0.1004
- 8.072
- 7
- 11.3
- 1655
- 164
- 0.1004
- 7.840
- 8
- 12.0
- 2186
- 216
- 0.1004
- 7.355
- 9
- 13.2
- 2887
- 381
- 0.1338
- 6.703
- 10
- 13.5
- 1705
- 169
- 0.1004
- 6.557
- 11
- 14.1
- 154
- 30
- 0.2007
- 6.275
- 12
- 14.7
- 803
- 79
- 0.1004
- 6.035
- 13
- 14.9
- 1346
- 178
- 0.1338
- 5.942
- 14
- 15.8
- 1556
- 154
- 0.1004
- 5.613
- 15
- 16.0
- 3339
- 441
- 0.1338
- 5.527
- 16
- 16.7
- 1845
- 183
- 0.1004
- 5.308
- 17
- 17.3
- 2835
- 281
- 0.1004
- 5.127
- 18
- 17.6
- 1252
- 124
- 0.1004
- 5.049
- 19
- 18.0
- 2183
- 216
- 0.1004
- 4.939
- 20
- 19.2
- 2303
- 228
- 0.1004
- 4.622
- 21
- 19.8
- 1298
- 128
- 0.1004
- 4.475
- 22
- 20.3
- 788
- 78
- 0.1004
- 4.373
- 23
- 20.6
- 1039
- 103
- 0.1004
- 4.317
- 24
- 21.1
- 882
- 116
- 0.1338
- 4.211
- 25
- 21.7
- 390
- 38
- 0.1004
- 4.103
- 26
- 22.3
- 1919
- 253
- 0.1338
- 3.990
- 27
- 22.7
- 1805
- 179
- 0.1004
- 3.923
- 28
- 23.0
- 4043
- 467
- 0.1171
- 3.861
- 29
- 23.5
- 650
- 86
- 0.1338
- 3.792
- 30
- 24.0
- 8677
- 1002
- 0.1171
- 3.711
- 31
- 24.7
- 229
- 30
- 0.1338
- 3.600
- 32
- 25.1
- 1246
- 164
- 0.1338
- 3.543
- 33
- 25.6
- 1659
- 219
- 0.1338
- 3.473
- 34
- 25.9
- 1773
- 175
- 0.1004
- 3.442
- 35
- 26.3
- 695
- 69
- 0.1004
- 3.385
- 36
- 26.6
- 401
- 46
- 0.1171
- 3.355
- 37
- 27.0
- 2800
- 370
- 0.1338
- 3.300
- 38
- 27.6
- 1415
- 140
- 0.1004
- 3.230
- 39
- 28.0
- 3250
- 429
- 0.1338
- 3.186
- 40
- 28.4
- 1513
- 250
- 0.1673
- 3.144
- 41
- 29.1
- 1456
- 144
- 0.1004
- 3.068
- 42
- 29.6
- 1943
- 192
- 0.1004
- 3.022
- 43
- 30.1
- 3637
- 540
- 0.1506
- 2.967
- 44
- 30.5
- 707
- 117
- 0.1673
- 2.929
- 45
- 30.9
- 596
- 59
- 0.1004
- 2.897
- 46
- 31.8
- 577
- 76
- 0.1338
- 2.816
- 47
- 32.0
- 1080
- 107
- 0.1004
- 2.796
- 48
- 32.5
- 512
- 51
- 0.1004
- 2.756
- 49
- 32.9
- 1268
- 167
- 0.1338
- 2.726
- 50
- 33.4
- 1180
- 117
- 0.1004
- 2.685
310 more elements
A pharmaceutical composition comprising as active ingredient an effective amount of acceptable, inert and non-toxic carriers.
Dependencies are inferred from the claim text.